We are the only company leveraging
unbiased spatial analytics and explainable AI to get to the
“why” in precision pathology


Spatial Analytics

Explainable AI


Why Unbiased Spatial Analytics?

It is now well understood that complex spatial relationships, the emergence of intermediate cell types and states, as well as communications between cells in tissues are critical components of disease progression and must be major drivers for solutions in precision pathology.

We are the only company that can

  • Identify functionally relevant transition cell states and fusion cell types
  • Discover heterogeneous microdomains associated with disease progression and outcomes
  • Reveal pathway interactions,signaling networks,potential molecular targets and drugs with microdomain-specific spatial systems pathology

Why Explainable AI?

Pathologists and disease experts require transparency and trust in applying computational and systems pathology, not black-box deep learning AI with biased heatmaps as substitutes for explanations. According to experts “xAI will be the game changer in computational pathology”.

We are the only company that can

  • Explain why a particular recommendation is made in a clinician understandable language
  • Build trust and confidence in decisions
    recommended by the algorithms
  • Deliver information and actionable knowledge
    with xAI guides to pathologists and disease
    specific clinicians who remain in full control to
    make the final decisions

Are you leveraging the power of

Precision Pathology?

Learn more about why explainable AI and next generation spatial analytics make a
difference in precision pathology

Download Whitepaper

Download Whitepaper

Subscribe to our Newsletter

* indicates required

S. Chakra Chennubhotla, PhD


Chakra earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Chakra was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.

Chakra co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Chakra’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.

Submit your Resume

B. Dusty Majumdar, PhD


B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

D. Lansing Taylor, PhD


Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.

Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.